Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO) and Dr. David Anderson in the role of Chief Scientific Officer (CSO). Dr. Baskin-Bey’s vast experience in leading global clinical development and regulatory strategy across multiple therapeutic areas will strengthen the clinical development program as...
Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the co-authors Tomas Hode, Wei Chen, and Sui Kit “Samuel” Lam on the T-Cell Paper publication in Clinical and Translational Medicine July 2022 issue. Check out this pivotal publication on how immunological remodeling of T-cells can...
Dr. Theresa Visarius, VP of Business Development at Immunophotonics, Inc. will be attending 2022 Swiss MedTech Day on Tuesday, June 14, 2022 in Kursaal Bern Switzerland.
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the Society of Interventional Radiology Annual Scientific Meeting (SIR) in Boston, MA June 11 – 16, 2022.
Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...
Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today if it weren’t for the entire team, many of whom are featured in this segment. Great Job Abby Delawder, Chun Fung (Johnny) Wong, Siu Kit (Samuel) Lam, Lu Alleruzzo, Tomas Hode. To View Click Here
The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day on Tuesday, May 3rd in the Clinical Stage Development Company category.
Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal Investigator spoke at the US Oncology Research BioTech Day, Early Development Program (EDP) Summit in Coronado, California, on April 27, 2022 at 1:00 p.m. in the Glorietta Room. Immunophotonics thanks Dr. Dan Von Hoff and...
Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a systemic immunotherapy against cancer. Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the European Conference on Interventional Oncology (EICO 2022) in Vienna, Austria April 24 – 27, 2022. This...
Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech pioneer and serial entrepreneur, joins a biotech-savvy slate of experts currently serving on the Board of Immunophotonics and brings a complementary set of proficiencies to the Board’s wealth of expertise within the pharmaceutical industry. Read...
